Shares of Trius Therapeutics (TSRX +5.6%) gain this morning after the company announced late...


Shares of Trius Therapeutics (TSRX +5.6%) gain this morning after the company announced late yesterday that it's received a Notice of Allowance from the USPTO on an application related to its tedizolid phosphate patent portfolio. The new application protects a therapeutic combination of the experimental medicine with a currently available antibiotic daptomycin. Together, TSRX claims the medicines can prevent the development of certain strains of staph infection.

From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs